Top in endocrinology: Oral anticoagulants and bone density, glycemic control trends
Click Here to Manage Email Alerts
Researchers said that a new study examining the impact of oral anticoagulants on bone health underscores the importance of assessing patients who are taking these medications for bone mineral density and quality.
A review of the findings was the top story in endocrinology last week.
Another top story was about fluctuations in glycemic control over the last 20 years in the United States. Data revealed that the proportion of adults with diabetes who met glycemic targets peaked at 57.4% from 2007 to 2010, then declined to 50.5% from 2015 to 2018.
Read these and more top stories in endocrinology below:
Oral anticoagulants may lower bone density, trabecular bone score
Adults prescribed any oral anticoagulation therapy have lower bone mineral density and trabecular bone score compared with controls, with a stronger negative effect observed among those prescribed warfarin, data published in Bone show. Read more.
Fewer US adults with diabetes achieving glycemic, BP targets since 2010
The percentage of U.S. adults with diabetes meeting glycemic and BP control targets declined from 2010 to 2018 after steadily increasing from 1999 to 2010, according to data published in The New England Journal of Medicine. Read more.
Thyroid groups: Perioperative risk stratification paramount in cancer treatment plan
Accurate risk stratification during the immediate perioperative period that incorporates molecular theranostics can help better guide decision-making for thyroid cancer treatment, according to a new joint statement published in Thyroid. Read more.
CVD risk factors rise with age, BMI for US firefighters
Firefighters who have a higher BMI and are older are more likely to have a higher prevalence of CVD risk factors, according to a study published in Obesity. Read more.
More youths with type 1 diabetes meet time-in-range goal with hybrid closed-loop system
The percentage of youths with type 1 diabetes spending at least 70% time in range more than doubled after 3 months of using a hybrid closed-loop insulin delivery system, according to a study published in Diabetes Technology & Therapeutics. Read more.